Display options
Share it on

Front Immunol. 2021 Dec 08;12:781185. doi: 10.3389/fimmu.2021.781185. eCollection 2021.

Indoleamine 2, 3 Dioxygenase 1 Impairs Chondrogenic Differentiation of Mesenchymal Stem Cells in the Joint of Osteoarthritis Mice Model.

Frontiers in immunology

Murad Alahdal, Rongxiang Huang, Li Duan, Deng Zhiqin, Ouyang Hongwei, Wencui Li, Daping Wang

Affiliations

  1. Hand and Foot Surgery Department, Shenzhen Second People's Hospital (The First Hospital Affiliated to Shenzhen University), Shenzhen, China.
  2. Shenzhen Key Laboratory of Tissue Engineering, Shenzhen Laboratory of Digital Orthopedic Engineering, Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology, Shenzhen Second People's Hospital (The First Hospital Affiliated to Shenzhen University, Health Science Center), Shenzhen, China.
  3. Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China.

PMID: 34956209 PMCID: PMC8693178 DOI: 10.3389/fimmu.2021.781185

Abstract

Osteoarthritis (OA) is a serious joint inflammation that leads to cartilage degeneration and joint dysfunction. Mesenchymal stem cells (MSCs) are used as a cell-based therapy that showed promising results in promoting cartilage repair. However, recent studies and clinical trials explored unsatisfied outcomes because of slow chondrogenic differentiation and increased calcification without clear reasons. Here, we report that the overexpression of indoleamine 2,3 dioxygenase 1 (IDO1) in the synovial fluid of OA patients impairs chondrogenic differentiation of MSCs in the joint of the OA mice model. The effect of MSCs mixed with IDO1 inhibitor on the cartilage regeneration was tested compared to MSCs mixed with IDO1 in the OA animal model. Further, the mechanism exploring the effect of IDO1 on chondrogenic differentiation was investigated. Subsequently, miRNA transcriptome sequencing was performed for MSCs cocultured with IDO1, and then TargetScan was used to verify the target of miR-122-5p in the SF-MSCs. Interestingly, we found that MSCs mixed with IDO1 inhibitor showed a significant performance to promote cartilage regeneration in the OA animal model, while MSCs mixed with IDO1 failed to stimulate cartilage regeneration. Importantly, the overexpression of IDO1 showed significant inhibition to Sox9 and Collagen type II (COL2A1) through activating the expression of β-catenin, since inhibiting of IDO1 significantly promoted chondrogenic signaling of MSCs (Sox9, COL2A1, Aggrecan). Further, miRNA transcriptome sequencing of SF-MSCs that treated with IDO1 showed significant downregulation of miR-122-5p which perfectly targets Wnt1. The expression of Wnt1 was noticed high when IDO1 was overexpressed. In summary, our results suggest that IDO1 overexpression in the synovial fluid of OA patients impairs chondrogenic differentiation of MSCs and cartilage regeneration through downregulation of miR-122-5p that activates the Wnt1/β-catenin pathway.

Copyright © 2021 Alahdal, Huang, Duan, Zhiqin, Hongwei, Li and Wang.

Keywords: IDO1 inhibitor; MSCs; cartilage regeneration; miR-122-5p; osteoarthritis

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Sci Rep. 2018 Jun 29;8(1):9869 - PubMed
  2. Front Immunol. 2020 Aug 18;11:1861 - PubMed
  3. Nat Rev Rheumatol. 2015 Apr;11(4):206-12 - PubMed
  4. Biochem Biophys Res Commun. 2014 Oct 31;453(4):810-6 - PubMed
  5. Arthritis Res Ther. 2010;12(4):R127 - PubMed
  6. Dev Dyn. 2010 Jan;239(1):56-68 - PubMed
  7. Am J Transl Res. 2020 Jun 15;12(6):2322-2343 - PubMed
  8. J Tissue Eng. 2020 Aug 26;11:2041731420943839 - PubMed
  9. BioDrugs. 2018 Jun;32(3):183-192 - PubMed
  10. Stem Cell Res Ther. 2012 Jul 09;3(4):25 - PubMed
  11. Curr Rheumatol Rep. 2017 Sep;19(9):53 - PubMed
  12. Clin Immunol. 2017 Jun;179:8-16 - PubMed
  13. Autoimmunity. 2014 Sep;47(6):409-18 - PubMed
  14. J Rheumatol. 2013 Jun;40(6):903-9 - PubMed
  15. Mol Cancer Res. 2019 Jan;17(1):299-309 - PubMed
  16. Curr Rev Musculoskelet Med. 2012 Sep;5(3):236-43 - PubMed
  17. Arthritis Rheum. 2009 May;60(5):1342-51 - PubMed
  18. Nat Rev Rheumatol. 2015 Jan;11(1):21-34 - PubMed
  19. Biol Cell. 2010 Aug 27;102(10):549-60 - PubMed
  20. Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):9332-9336 - PubMed
  21. Arthritis Res Ther. 2007;9(3):R50 - PubMed
  22. Rheumatology (Oxford). 2014 Feb;53(2):338-45 - PubMed
  23. Nat Genet. 1997 Jun;16(2):174-8 - PubMed
  24. J Immunol. 2014 Mar 1;192(5):2082-2090 - PubMed
  25. Ann Rheum Dis. 2019 Jun;78(6):826-836 - PubMed
  26. Curr Opin Rheumatol. 2013 Jan;25(1):119-26 - PubMed
  27. Stem Cell Res Ther. 2018 Nov 28;9(1):329 - PubMed
  28. Arthritis Res Ther. 2007;9(5):R107 - PubMed
  29. J Orthop Res. 2019 Jun;37(6):1229-1235 - PubMed
  30. Int J Tryptophan Res. 2013 Jul 21;6(Suppl 1):67-73 - PubMed
  31. Nat Commun. 2018 Dec 4;9(1):5154 - PubMed
  32. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2601-8 - PubMed

Publication Types